Form 4: Thermo Fisher Scientific CEO Marc Casper Sells Shares Under 10b5-1 Plan

Thermo Fisher Scientific's CEO, Marc Casper, executed multiple sales of common stock on November 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 8, 2024, Marc N. Casper, the Chairman and CEO of Thermo Fisher Scientific Inc., sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 7, 2024.
• The transactions involved multiple sales at varying prices, ranging from $550.17 to $554.98 per share.
• A total of 9,000 shares were sold directly.
• After the reported transactions, Casper directly owns 121,191.54 shares of common stock.
• Casper also indirectly owns shares through Floral Park Associates, Inc. (14,608 shares), Alison Casper 2020 Irrevocable Trust (11,300 shares), and MNC 2020 Irrevocable Trust (5,000 shares).
• Casper disclaims beneficial ownership of the securities held by the Alison Casper 2020 Irrevocable Trust and MNC 2020 Irrevocable Trust, except to the extent of any pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is neutral as it simply reports stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Executive stock sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of acting on non-public information. The market will likely interpret this sale in the context of Casper's overall holdings and the company's performance.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, depending on how the market interprets the transaction.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates